Sun Pharmaceutical Industries Ltd. closed 8.26% below its 52-week high of 1,885.00 rupees, which the company reached on ...

Natco’s escalates the legal battle over semaglutide, one of the world’s most valuable and closely contested pharmaceutical ...

A revolution in India’s weight-loss market is coming. As Semaglutide’s patent ends in 2026, Sun Pharma, Lupin, Torrent, and ...

Indian drugmakers, known for their chemistry and prowess in making generics—cheaper copies of innovative drugs—for the world, ...

Vishal Manchanda, Pharma Analyst at Systematix Group, said that when it comes to investing in the GLP-1 theme, the Indian ...

The US-Venezuela tensions has turned the spotlight on shares of companies like Indian Oil Corp, Oil India, Sun Pharma, Dr ...

Capture and trial of Maduro and subsequent US actions in Venezuela could reshape oil flows, affect Indian energy and pharma ...

As tensions rise between the US and Venezuela, analysts assess whether the conflict could impact India’s oil import bill and ...

India’s exposure to Venezuela spans multiple sectors, led by oil and gas. ONGC holds equity stakes in two oil projects in the ...

The year also reinforced a long-standing strength of Indian pharma: its ability to scale through strategic consolidation.

In 2025, the BSE Healthcare Index which is represented by mostly pharma companies underperformed the Sensex, declining ...

India is expected to be the witness the fiercest competition in 2026, with Semaglutide's patent expiry in March triggering launches by 10-15 players within the following three months.